<DOC>
	<DOCNO>NCT00546481</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy intravenous Mircera treatment correction anemia patient chronic kidney disease dialysis . Patients randomize receive either Mircera 0.6 micrograms/kg i.v . every 2 week , epoetin 3 time per week i.v . accord approve treatment recommendation . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Correction Anemia Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; maintenance hemodialysis peritoneal dialysis &gt; =2 week screen , screen period . previous therapy epoetin within 8 week prior screen ; overt gastrointestinal bleeding within 8 week screen screening period ; RBC transfusion within 8 week screen screening period ; active malignant disease except nonmelanoma skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>